相关实验视频

Updated: Jan 15, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

[与肺部疾病相关的肺高血压]

Athiththan Yogeswaran¹, Dirk Skowasch², Vasile Foris^3,4

¹Department of Internal Medicine, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Gießen (Germany), Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI), Gießen, Deutschland.

Pneumologie (Stuttgart, Germany)

|October 6, 2025

概括

慢性肺部疾病 (PH-CLD) 中的肺高血压是常见的和低诊断的,影响患者的预后. 本声明提供了基于更新的WSPH建议的PH-CLD的实用诊断和治疗指南.

科学领域:

心脏病学心脏病学
肺部病理学肺部病理学
呼吸系统医学呼吸系统医学

背景情况:

与慢性肺病相关的肺高血压 (PH-CLD) 是一种普遍且经常被误诊的疾病.
PH-CLD显著恶化患者的预后和生活质量.
患者的异质性强调了需要量身定制的诊断和治疗策略.

研究的目的:

总结第七届肺高血压世界研讨会 (WSPH) 致力于PH-CLD的特别工作组的主要建议.
对PH-CLD的诊断和治疗方法的现有证据进行批判性评估.
提出用于管理PH-CLD患者的实际算法.

主要方法:

审查和综合第七届世卫组织第十一届工作组报告.
对关于PH-CLD的当前科学文献进行批判性评估.
分析与原始 WSPH 建议的偏差.

主要成果:

强调系统诊断和PH-CLD的详细表型.
突出了针对PH的向疗法的治疗结果的变化,特别是在COPD中.
确定预后的关键决定因素,包括肺病类型和PH严重程度.

结论:

需要为PH-CLD提供标准化诊断途径.
建议在某些慢性肺部疾病中对PH向治疗采取谨慎措施.
开发实用的临床算法对于最佳的患者管理至关重要.

更多相关视频

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...